Breaking News

BMS to Acquire MyoKardia for $13.1B

Promising portfolio of pipeline candidates strengthens and extends BMS’ cardiovascular franchise.

By: Contract Pharma

Contract Pharma Staff

Bristol Myers Squibb (BMS) and MyoKardia have entered a merger agreement under which BMS will acquire MyoKardia for $13.1 billion. The transaction was unanimously approved by both the BMS and MyoKardia boards and is anticipated to close during the fourth quarter of 2020.   MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. Through the transaction, BMS gains mavacamten, a potential first-in-cl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters